RNA therapeutics for mood disorders: current evidence towards clinical trials - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Expert Opinion on Investigational Drugs Année : 2021

RNA therapeutics for mood disorders: current evidence towards clinical trials

Résumé

Introduction: Mood disorders are severe yet frequent psychiatric disorders worldwide, comprising major depressive disorder (MDD) and bipolar disorders (BD). Their treatment remains poorly effective. Recently, growing evidence for epigenetic mechanisms has emerged. Consequently, a great interest in a novel pharmacological class arose: RNA therapeutics. Areas covered: We conducted a systematic review of RNA therapeutics -antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), and micro-RNA (miRNA) therapeutics- for the treatment of mood disorders studied in pre-clinical animal models listed in PubMed, in clinical trials registered in ClinicalTrials.gov and available on the market by combining literature search and Food and Drug Administration and European Medicine Agency online databases. Eighteen pre-clinical studies investigated the antidepressant effects of RNA therapeutics. However, even though there is an increasing number of marketing authorizations and clinical trials for the past twenty years, no RNA therapeutic has reached the clinical development pipeline for the treatment of psychiatric disorders yet. Expert opinion: Several promising RNA therapeutics have been tested in pre-clinical studies for MDD, whereas no molecule has been developed for BD. There are several issues to address before reaching clinical development and new challenges include stratifying patient population and predicting therapeutic response.
Fichier principal
Vignette du fichier
RNA therapeutics for mood disorders - current evidence towards clinical trials.pdf (1.11 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03361479 , version 1 (05-10-2021)

Identifiants

Citer

Marguerite Le Marois, Eleni Tzavara, El Chérif Ibrahim, Olivier Blin, Raoul Belzeaux. RNA therapeutics for mood disorders: current evidence towards clinical trials. Expert Opinion on Investigational Drugs, 2021, ⟨10.1080/13543784.2021.1928073⟩. ⟨hal-03361479⟩
33 Consultations
330 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More